New targets for the prevention and treatment of cirrhotic portal vein thrombosis
10.3760/cma.j.cn501113-20240229-00100
- VernacularTitle:肝硬化门静脉血栓防治的新靶点
- Author:
Yuwei WANG
1
;
Huiguo DING
Author Information
1. 首都医科大学附属北京佑安医院肝病消化中心，北京 100000
- Keywords:
Liver cirrhosis;
Portal vein thrombosis;
Treatment;
Risk factors;
Intestinal flora;
Prevention;
Target point
- From:
Chinese Journal of Hepatology
2024;32(6):484-488
- CountryChina
- Language:Chinese
-
Abstract:
Portal vein thrombosis (PVT) is divided into cirrhotic and non-cirrhotic PVTs. The incidence rate of PVT varies greatly among different clinical stages of cirrhosis, with an overall incidence rate of about 13.92%, and the prevalence of cirrhotic PVT following splenectomy is as high as 60%. The pathogenesis of cirrhotic PVT is still unclear. However, the activation of Janus kinase/signal transduction and activator transcription signaling pathways, the rise in the expression of von Willebrand factor, and the gut microbiota along with its metabolite trimethylamine-N-oxide play an important role in the injury of vascular endothelial cells and the formation of PVT in cirrhosis. Therefore, these could be a new target for cirrhotic PVT prevention and treatment.
